Answers are grounded in this paper and cite their sources.
// Haiying Cheng 1 , Zhenfeng Zhang 2 , Ruth Rodriguez-Barrueco 3 , Alain Borczuk 4 , Huijie Liu 1 , Jiyang Yu 5, 7 , Jose M. Silva 3 , Simon K. Cheng 6 , Roman Perez-Soler 1 , Balazs Halmos 1, 8 1 Department of Oncology, Albert Einstein College of Medicine of Yeshiva University/Montefiore Medical Center, Bronx, NY, USA 2 Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Center of Medical Imaging and Image-Guided Therapy, Guangzhou, China 3 Icahn School of Medicine at Mount Sinai, New York, NY, USA 4 Department of Pathology, Weill Cornell University Medical Center, New York, NY, USA 5 Department of Biomedical Informatics, Columbia University, New York, NY, USA 6 Department of Radiation Oncology, Columbia University College of Physicians and Surgeons, New York, NY, USA 7 Department of Precision Medicine, Oncology Research Unit, Pfizer Inc., Pearl River, NY, USA 8 Division of Hematology/Oncology, Herbert Irving Comprehensive Cancer Center, New York Presbyterian Hospital-Columbia University Medical Center, New York, NY, USA Correspondence to: Haiying Cheng, email: hcheng@montefiore.org Keywords: lung cancer, RNAi screen, YAP1, platinum resistance, radiation Received: August 27, 2015 Accepted: November 21, 2015 Published: December 22, 2015 ABSTRACT Survival for lung cancer patients remains dismal and is largely attributed to treatment resistance. To identify novel target genes the modulation of which could modify platinum resistance, we performed a high-throughput RNAi screen and identified Yes-associated protein (YAP1), a transcription coactivator and a known oncogene, as a potential actionable candidate. YAP1 ablation significantly improved sensitivities not only to cisplatin but also to ionizing radiation, both of which are DNA-damaging interventions, in non-small cell lung cancer (NSCLC) cells. Overall YAP1 was expressed in 75% of NSCLC specimens, whereas nuclear YAP1 which is the active form was present in 45% of 124 resected NSCLC. Interestingly, EGFR -mutated or KRAS -mutated NSCLC were associated with higher nuclear YAP1 staining in comparison to EGFR/KRAS wild-type. Relevantly, YAP1 downregulation improved sensitivity to erlotinib, an EGFR inhibitor. A pharmacological inhibitor of YAP1 signaling, verteporfin also synergized with cisplatin, radiation and erlotinib in NSCLC cells by potentiating cisplatin and radiation-related double-stranded breaks and decreasing expression of YAP1 and EGFR. Taken together, our study is the first to indicate the potential role of YAP1 as a common modulator of resistance mechanisms and a potential novel, actionable target that can improve responses to platinum, radiation and EGFR-targeted therapy in lung cancer.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: